Compare Expensify Inc (EXFY) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Expensify Inc trades at $2.42 (market cap $208.82M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.62 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 121× Expensify Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| EXFY | RPRX | |
|---|---|---|
Market Cap | $208.82M | $25.27B |
Volume | 456,102 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $2.72 | $63.96 |
52-Week Low | $0.75 | $35.44 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $148.44M | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.
The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
